Dupix­ent wins FDA OK for asth­ma; Seres poach­es new CMO from As­traZeneca

→ Sanofi and Re­gen­eron won FDA ap­proval to mar­ket Dupix­ent for asth­ma. “Dupix­ent is now ap­proved in the U.S. for two im­por­tant groups of un­con­trolled asth­ma pa­tients – those who are mod­er­ate-to-se­vere with an eosinophilic phe­no­type or those with oral cor­ti­cos­teroid-de­pen­dent asth­ma,” said George Yan­copou­los, pres­i­dent and CSO of Re­gen­eron.

→ As­traZeneca vet Kevin Hor­gan is jump­ing over to Cam­bridge, MA-based Seres as its new CMO. “Kevin is an ac­com­plished drug de­vel­op­er with ex­ten­sive ex­pe­ri­ence suc­cess­ful­ly lead­ing nu­mer­ous mid- and late-stage clin­i­cal pro­grams to ap­proval. Seres’ R&D ef­forts are in­creas­ing­ly fo­cused on ear­ly and lat­er stage im­muno­log­i­cal in­di­ca­tions, and Kevin’s deep clin­i­cal back­ground in these ar­eas makes him very well suit­ed to lead our clin­i­cal de­vel­op­ment stud­ies,” said Seres CEO Roger Pomer­antz.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER